Dr. Slassi was the Founder, President and Chief Scientific Officer of Fluorinov Pharma Inc. acquired by Trillium in January 2016. Dr. Slassi has over 30 years of experience in the successful identification of small molecule drug candidates across multiple therapeutic areas including Neurology, Oncology, Immunology and Gastro-intestinal. Prior to founding Fluorinov, Dr. Slassi was Director and Vice President of Medicinal Chemistry and Manufacturing & Drug Development at NPS Pharmaceuticals and Cascade Therapeutics, respectively, and earlier he held management and scientific positions at Allelix Biopharmaceuticals Inc., Boehringer Ingelheim Research Inc., and Rhône Poulenc.